Dr. Karine Cohen-Solal graduated from Paris University, France in 1994 in Molecular and Cellular Biology and Endocrinology. In 1999, she started a career in Cancer Research at Rutgers University. For the last 19 years, Dr. Cohen-Solal has relentlessly developed cancer research programs in receptor-based dysregulated cellular pathways in cancer and the emergence of resistance mechanisms against natural tumor suppressive mechanisms and against drug therapy. During her 10 years as a Principal Investigator and faculty member at Rutgers University-Robert Wood Johnson Medical School, Dr. Cohen-Solal received several awards including the prestigious Research Scholar Grant from the American Cancer Society, and awards for the New Jersey Commission on Cancer Research. Dr. Cohen-Solal’s breakthroughs involve the identification of a new type of receptor in melanoma genesis and the disruption of natural tumor suppressive mechanisms in disseminating melanomas. Dr. Cohen-Solal is co-founder and Chief Scientific Officer of Lambda Pharmaceuticals, a company dedicated to providing cutting edge therapies for viral infections, cancer and developmental disorders.